drugset / Trial / NCT01523990
A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients
RandomizedSingle-groupQuadruple-blindTreatment
Summary
A Safety Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in HCV Genotype 1 Infected Patients
Timeline
- Start
- 2011-10
- Primary completion
- 2012-04
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furaprevir | Small molecule | 50 mg | Oral |
| Subject | Furaprevir | Small molecule | 100 mg | Oral |
| Subject | Furaprevir | Small molecule | 200 mg | Oral |
| Subject | Furaprevir | Small molecule | 400 mg | Oral |
| Subject | Furaprevir | Small molecule | 600 mg | Oral |
| Subject | Furaprevir | Small molecule | 800 mg | Oral |